Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$5.38 USD
+0.27 (5.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $5.36 -0.02 (-0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.38 USD
+0.27 (5.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $5.36 -0.02 (-0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal
by Zacks Equity Research
Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.
Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 179%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 179.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?
by Zacks Equity Research
Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.
Global Blood (GBT) Initiates Phase II Study on SCD Candidate
by Zacks Equity Research
Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the trial
BioMarin (BMRN) Gets CHMP Nod for Hemophilia Drug Roctavian
by Zacks Equity Research
BioMarin (BMRN) receives a positive CHMP opinion for Roctavian, its gene therapy for treating adults with hemophilia A. The European Commission's decision is expected by the third quarter of 2022.
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 238%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study
by Zacks Equity Research
Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.
Rhythm Pharma (RYTM) Down on Mixed Imcivree Regulatory Updates
by Zacks Equity Research
The FDA approves label expansion of Rhythm Pharma's (RYTM) Imcivree to include Bardet-Biedl Syndrome patients. However, the FDA provides CRL for label expansion of the drug in Alstrom syndrome.
How Much Upside is Left in Anavex Life Sciences (AVXL)? Wall Street Analysts Think 286%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 286.4% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.
Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease
by Zacks Equity Research
Apellis (APLS) and Sobi dose the first patient in phase III VALIANT study evaluating pegcetacoplan in primary immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Stock up.
Praxis (PRAX) Tanks on Negative Data From Depression Study
by Zacks Equity Research
Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.
GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix
by Zacks Equity Research
The FDA approves GSK's Priorix vaccine for active immunization for the prevention of measles, mumps and rubella in individuals aged 12 months and older.
Immunocore (IMCR) Up on Deal With Sanofi for Skin Cancer Study
by Zacks Equity Research
Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
by Zacks Equity Research
Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.
Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug
by Zacks Equity Research
Aeglea (AGLE) gets a Refusal to File letter from the FDA related to the biologics license application for pegzilarginase to treat arginase 1 deficiency. Stock down.
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is the Options Market Predicting a Spike in Anavex (AVXL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Anavex (AVXL) stock based on the movements in the options market lately.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Anavex (AVXL) to Report Q3 Earning: What's in the Cards?
by Zacks Equity Research
On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.
Company News for Jun 29, 2021
by Zacks Equity Research
Companies in the news are: NTLA, AVXL, MNKD, KYMR
Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.
Implied Volatility Surging for Anavex Life Sciences (AVXL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.
Company News for Jun 15, 2021
by Zacks Equity Research
Companies In The News Are: RIDE, PHG, AVXL, RDS.A